Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The purpose of this study was to compare two analog insulin therapies (prandial premixed therapy [PPT] versus basal/bolus therapy [BBT]) in type 2 diabetic patients previously treated with insulin glargine (≥30 units/day) plus oral agents, with the aim of demonstrating noninferiority of PPT to BBT. RESEARCH DESIGN AND METHODS—Patients were randomly assigned to PPT (lispro mix 50/50: 50% insulin lispro protamine suspension and 50% lispro; n = 187) t.i.d. with meals or BBT (glargine at bedtime plus mealtime lispro; n = 187) in a 24-week, multicenter, open-label, noninferiority trial. Investigators could replace lispro mix 50/50 with lispro mix 75/25 at the evening meal if the fasting plasma glucose target was unachievable. RESULTS—Baseline A1C was similar (PPT 8.8%; BBT 8.9%; P = 0.598). At week 24, A1C was lower with BBT (6.78 vs. 6.95%, P = 0.021). A1C was reduced significantly from baseline for both therapies (P < 0.0001). The difference in A1C change from baseline to the end point (BBT minus PPT) was −0.22% (90% CI −0.38 to −0.07). Noninferiority of PPT to BBT was not demonstrated based on the prespecified noninferiority margin of 0.3%. The percentages of patients achieving target A1C <7.0% (PPT versus BBT, respectively) were 54 vs. 69% (P = 0.009) and for target ≤6.5% were 35 vs. 50% (P = 0.01) but did not differ for target ≤6.0% or <7.5%. Rates of hypoglycemia were similar for both groups. CONCLUSIONS—Although noninferiority of PPT to BBT was not demonstrated, findings for A1C reduction, percentage of patients achieving A1C targets, hypoglycemia, and number of required injections should be considered in the individual decision-making process of advancing insulin replacement to PPT versus BBT in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 1×
“The progressive deterioration of pancreatic beta-cell function in type 2 diabetes necessitates the advancement of treatment over time for most patients (1, 2 ). For patients that have failed oral antihyperglycemic agents (OHAs), basal insulin is often initiated (3-10).”
BackgroundStandards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434 · cited 1×
“For patients that have failed oral antihyperglycemic agents (OHAs), basal insulin is often initiated (3-10).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420
Herman, W. H., Ilag, L. L., Johnson, S. L., Martin, C. L., Sinding, J., Al Harthi, A., Plunkett, C. D., LaPorte, F. B., Burke, R., Brown, M. B., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1568 · Cited by 265
Cited by
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Rys, P., Wojciechowski, P., Rogoz-Sitek, A., Niesyczyński, G., Lis, J., Syta, A., & Malecki, M. T. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0698-4 · Cited by 101
Bergenstal, R. M., Johnson, M., Passi, R., Bhargava, A., Young, N., Kruger, D. F., Bashan, E., Bisgaier, S. G., Isaman, D. J. M., & Hodish, I. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30368-x · Cited by 88
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
Self-citationBlevins, T., Zhang, Q., Frias, J. P., Jinnouchi, H., & Chang, A. M. (2020) · Diabetes Care · doi:10.2337/dc19-2550 · Cited by 69
Insulin analogues: an example of applied medical science
Sheldon, B., Russell‐Jones, D., & Wright, J. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01015.x · Cited by 69
Mitchell, B. D., He, X., Sturdy, I. M., Cagle, A. P., & Settles, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15831.or · Cited by 46
Tannic acid-based sustained-release system for protein drugs
Utatsu, K., Motoyama, K., Nakamura, T., Onodera, R., & Higashi, T. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123229 · Cited by 31
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Metadata
- Authors
- Rosenstock, J., Ahmann, A. J., Colon, G., Scism-Bacon, J., Jiang, H., & Martin, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-01-01
- Volume
- 31
- Issue
- 1
- Pages
- 20-25
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2170031373
- Cited by
- 191
- References
- 8
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.